Description

Ethyl6-Bromo-7-Fluoro-4-Oxo-1,4-Dihydroquinoline-3-Carboxylate is a high-purity, advanced pharmaceutical intermediate belonging to the quinoline carboxylic acid ester family. This compound is valued for its role as a critical building block in the synthesis of complex active pharmaceutical ingredients (APIs), particularly those targeting bacterial infections and other therapeutic areas. It is essential for R&D laboratories and manufacturers in the pharmaceutical and fine chemical industries seeking reliable, high-quality intermediates for process development and scale-up.

Application

• Pharmaceutical Intermediate: A key precursor in the synthesis of novel fluoroquinolone antibiotic candidates and other biologically active quinoline derivatives.
• Research & Development: Used in medicinal chemistry for structure-activity relationship (SAR) studies and the development of new therapeutic agents.
• Chemical Synthesis: Serves as a versatile building block for introducing the 6-bromo-7-fluoro-quinoline scaffold into more complex molecular architectures.
• API Manufacturing: Employed in the commercial-scale production of active pharmaceutical ingredients under controlled GMP environments.
• Reference Standard: Can be utilized as an analytical standard for quality control and method validation in pharmaceutical analysis.

Basic Information

Product Name	Ethyl6-Bromo-7-Fluoro-4-Oxo-1,4-Dihydroquinoline-3-Carboxylate
CAS No.	159727-93-2
Molecular Formula	C₁₂H₉BrFNO₃
Molecular Weight	314.11 g/mol
Synonyms	Ethyl 6-Bromo-7-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylate; 6-Bromo-7-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid ethyl ester; 3-Quinolinecarboxylic acid, 6-bromo-7-fluoro-1,4-dihydro-4-oxo-, ethyl ester; 1,4-Dihydro-6-bromo-7-fluoro-4-oxoquinoline-3-carboxylic Acid Ethyl Ester; Ethyl 6-bromo-7-fluoro-1,4-dihydro-4-oxoquinoline-3-carboxylate; 159727-93-2; 6-Bromo-7-fluoro-4-hydroxyquinoline-3-carboxylic acid ethyl ester
EINECS	Contact for details

Quality Control

Our products undergo rigorous quality testing to ensure compliance with industry standards for pharmaceutical intermediates. Each batch is characterized and controlled using advanced analytical techniques including HPLC, GC, NMR, and MS to confirm identity, purity, and consistency. Certificates of Analysis (COA) detailing all specifications and test results are available upon request. We adhere to a quality management system to support our commitment to supply reliability.

Storage

Preserve in a tightly closed container, protected from light. Store in a cool, dry, and well-ventilated area at controlled room temperature (15-25°C). Keep away from incompatible materials. For long-term storage, consider inert atmosphere conditions to maintain optimal stability.

Specification

Item	Specification
Appearance	White to off-white crystalline powder
Identification (IR)	Conforms to structure
Identification (HPLC)	Conforms to reference
Purity (HPLC)	≥ 98.0%
Loss on Drying	≤ 0.5%
Residue on Ignition	≤ 0.1%
Heavy Metals	≤ 20 ppm
Single Unknown Impurity (HPLC)	≤ 0.5%
Total Impurities (HPLC)	≤ 2.0%

Note: Specifications can be tailored. Please contact us for the detailed technical data sheet of a specific grade.